Corporate Banner
Satellite Banner
Crystallography
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sygnature Discovery and Proteros Biostructures Establish Strategic Alliance

Published: Wednesday, October 23, 2013
Last Updated: Wednesday, October 23, 2013
Bookmark and Share
Under the terms of the agreement, Sygnature and Proteros will collaborate to provide integrated services to advance clients’ drug discovery projects.

This new alliance adds an integral component to Sygnature’s ‘federated’ CRO Model, which provides fully-integrated drug discovery services to the pharmaceutical industry.

Dr Torsten Neuefeind, CEO, Co-founder at Proteros said, "Sygnature has a growing reputation as a provider of premium integrated drug discovery services.  Proteros has worked with Sygnature on a number of drug discovery projects, so we already have an established working relationship.  This strategic alliance combines the complementary skills of Proteros and Sygnature Discovery.  Proteros will continue to provide X-ray protein structure analysis independently, but will also be able to contribute to fully-integrated drug discovery programmes via Sygnature’s ‘federated’ CRO model.  Working closely together on drug discovery projects, we are confident that Proteros and Sygnature can advance clients’ programmes more efficiently and effectively.”

Commenting on the strategic alliance, Dr Simon Hirst, Sygnature’s CEO said, “Proteros has specialist skills in early stage drug discovery that are highly-complementary to our own.  Proteros has an outstanding reputation for providing unique and best-in-class technologies for X-ray protein crystallography, kinetic and thermodynamic profiling and tailor-made protein production.  Sygnature and Proteros have already collaborated on a number of challenging client projects.  The close working relationship that we have established will be cemented through this strategic alliance.  With the addition of Proteros to the ‘federated’ CRO Model, it enables Sygnature to offer its customers a world class, fully-integrated drug discovery service where novel compounds can be designed, synthesised and screened in vitro at Sygnature, X-ray protein structure analysis undertaken at Proteros, metabolic liability and toxicity assessed at Cyprotex and then tested at Saretius and Pneumolabs in pharmocodynamic and disease-relevant models.  This powerful federation of alliance partners will help accelerate our clients’ drug discovery programmes towards development.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Sygnature Discovery’s Group Invests in New Start Up, Peak Proteins
Investment is part of an ongoing strategy to build and expand the Group’s extensive capabilities.
Thursday, January 28, 2016
Scientific News
Human Astrovirus Structure Could Lead to Therapies, Vaccines
Study shows where neutralizing antibody binds to human astrovirus, a leading cause of viral diarrhoea in children, elderly, and the immune-compromised.
Drug Design Strategy to Improve Breast Cancer Treatment
Scientists develop novel structure-based drug design strategy aimed at altering the basic landscape of hormone-driven breast cancer treatment.
Crystals, Super Magnets in Drug Discovery
Scientists have produced larger superparamagnetic crystals that could revolutionise drug delivery.
Peer Review is in Crisis, But Should be Fixed, Not Abolished
After the time to get the science done, peer review has become the slowest step in the process of sharing studies, and some scientists have had enough.
Snapshots of Chemical Flipping a Biological Switch
X-ray laser gets first real-time snapshots of a chemical flipping a biological switch, opening new path to understanding how RNA works.
Uncovering Elusive Proteins
Researchers have determined the complete structure of elusive proteins, known as tetraspanins, for the first time.
Cannabinoid Receptor Structure Revealed
Scientists provided a detailed view of the primary molecule through which cannabinoids exert their effects on the brain. The findings might help guide the design of more targeted medicines with fewer side effects.
Alzheimer’s Treatment Moves a Step Closer
Merck scientists have reported the discovery of verubecestat, a structurally unique, orally bioavailable small molecule that has been shown to target the most visible sign of the disease in the brain.
Study Unocovers Cancer-Linked Protein’s Associates
Researchers have developed a new list of nearly 100 potential partners of a cancer-linked enzyme by studying its interactions with other proteins.
Scientists Uncover Why Hepatitis C Vaccine is Difficult to Make
Scientists have uncovered one reason why a successful hepatitis C vaccine continues to be elusive.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!